Moderna, Merck Fall After Melanoma Data Leak

Moderna and Merck shares plummeted after data on the companies' personalized melanoma vaccine wasn't enough to prove to investors that a new era of cancer treatments has arrived. Michelle Fay Cortez has more on "Bloomberg The Close." (Source: Bloomberg)